April 18, 2024 10:42 AM EDTUpdated 12:58 PM
Cell/Gene Tx
Manufacturing

J&J, Bris­tol My­ers race to am­pli­fy CAR-T man­u­fac­tur­ing to meet la­bel ex­pan­sion in mul­ti­ple myelo­ma

Anna Brown

News Reporter

John­son & John­son and Bris­tol My­ers Squibb are in­di­vid­u­al­ly gear­ing up their lentivi­ral pro­duc­tion and CAR-T prod­uct ca­pac­i­ties fol­low­ing their re­cent la­bel ex­pan­sions in mul­ti­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times